1
|
van Heerden X, Jansen C, Corcoran S, Price A, Kotze N, Rowan FE, Cleary MS. Novel Clinics and their Effect on the Elective Orthopaedic Waiting List. Ir Med J 2024; 117:898. [PMID: 38260711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
|
2
|
van Heerden X, Jansen C, Corcoran S, Price A, Kotze N, Rowan FE, Cleary MS. Novel Clinics and their Effect on the Elective Orthopaedic Waiting List. Ir Med J 2024; 117:898. [PMID: 38260710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
|
3
|
Duncan A, McDermott H, Corcoran S, Devine C, Barry C. Pyroglutamic acidosis caused by the combination of two common medicines prescribed in everyday practice. Oxf Med Case Reports 2023; 2023:omad048. [PMID: 37260733 PMCID: PMC10228107 DOI: 10.1093/omcr/omad048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 03/13/2023] [Accepted: 04/10/2023] [Indexed: 06/02/2023] Open
Abstract
We present the case of a 71-year-old female treated for infective endocarditis with flucloxacillin and paracetamol. Her clinical course became complicated by a blood-gas demonstrating a raised anion gap metabolic acidosis. The patient was diagnosed with pyroglutamic metabolic acidosis. This is a rare interaction between high dose flucloxacillin and paracetamol, and is an important complication to recognize.
Collapse
Affiliation(s)
- A Duncan
- Correspondence address. General Internal Medicine, Bon Secours, Dublin, Ireland. Tel: +353-0871206988; E-mail:
| | - H McDermott
- Department of Medicine, Bon Secours Hospital, Dublin, Ireland
- Department of Microbiology, Bon Secours, Dublin, Ireland
| | - S Corcoran
- Department of Medicine, Bon Secours Hospital, Dublin, Ireland
- Department of Microbiology, Bon Secours, Dublin, Ireland
| | - C Devine
- Department of Medicine, Bon Secours Hospital, Dublin, Ireland
- Department of Microbiology, Bon Secours, Dublin, Ireland
- Department of Pharmacy, Bon Secours, Dublin, Ireland
| | - C Barry
- Department of Medicine, Bon Secours Hospital, Dublin, Ireland
- Department of Microbiology, Bon Secours, Dublin, Ireland
| |
Collapse
|
4
|
O'Keeffe R, Redmond A, Leuthe L, Corcoran S. Review of Outcomes for Vaginal-Approach Cervical Cerclage in Women at Risk of Spontaneous Preterm Birth. Ir Med J 2023; 116:757. [PMID: 37555555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 08/10/2023]
|
5
|
Liu B, Shen S, Salehi E, Chen Y, Toumbacaris N, Allsop J, Anselmo C, Corcoran S, Kelly B, Magnoli R, Smith A, Emerzian M, Brockway-Marchello J, Bacotti D, Robson ME, Iyengar NM. Abstract P5-08-07: Dietary patterns among women with early-stage breast cancer from the Healthy Living Program. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p5-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Diet is a modifiable risk factor for breast cancer risk and mortality. Current guidelines recommend a diet that provides a diverse array of nutrients, comprised predominantly of fruits/vegetables and whole grains, with limited added sugar. The Healthy Living Program (HLP) is a clinical program at Memorial Sloan Kettering Cancer Center for patients with early-stage breast cancer that offers longitudinal, personalized lifestyle management starting at the time of diagnosis. Here, we report dietary patterns among the HLP cohort and association with baseline body mass index (BMI). Methods: We included all patients enrolled in the HLP from September 2020-February 2022. At the time of enrollment, participants complete a survey containing the National Cancer Institute (NCI) Dietary Screener Questionnaire (DSQ), which consists of consumption frequency questions for 26 food items over the past month. Total daily intake equivalents are calculated for foods from every diet factor group according to standard NCI DSQ scoring as follows: 1) Total daily cup equivalents of fruits/vegetables, which includes fruit, fruit juice, salad, potatoes, beans, other vegetables, tomato sauce, salsa, and pizza; 2) Total daily ounce equivalents of whole grains, which includes cereal, whole grain bread, whole grain rice, and popcorn; 3) Total teaspoon (tsp) equivalents of added sugars from candy, doughnuts, cookies/cake/pie, cereal, ice cream, and sugar-sweetened beverages including soda, fruit drinks, and sugar/honey in coffee/tea. Adherence to recommended daily intake of fruits/vegetables, whole grains, and added sugars was assessed as per the 2020-2025 Dietary Guidelines, the American Institute for Cancer Research, and the World Health Organization guidelines. Patient and tumor characteristics were abstracted from medical records. Results: Among the 399 patients included, the median age at diagnosis was 58 and median baseline BMI was 26.1 kg/m2. 45 patients had carcinoma in situ (11.3%), 296 had stage I disease (74.2%), 51 had stage II disease (12.8%), and 7 had stage III disease (1.8%). 316 had hormone-receptor positive disease (89.3%), 24 had HER2-positive disease (6.8%), and 26 had triple-negative disease (7.3%). 106 participants (27%) met the guideline recommendation of ≥4-5 cup equivalents of fruits/vegetables daily and 3 participants (0.8%) met the guideline recommendation of ≥3 ounces equivalents of whole grains daily. All patients in the cohort met the guideline recommendation of < 6 tsp equivalents of added sugars daily. Only 2 patients (0.5%) met guidelines for all three diet factors. Baseline BMI was significantly higher among patients who did not meet the recommended fruit/vegetable intake than among those who did (26.9 kg/m2 vs. 24.5 kg/m2, p=0.016). There were no significant differences in BMI between those who did and did not adhere to the other diet factor guidelines and no significant association between tumor stage or histology and dietary guideline adherence. Conclusion: Most patients with early-stage breast cancer did not meet the recommended daily intake of fruits/vegetables or whole grains. Participants who did not meet the fruit and vegetable intake guideline had significantly higher BMI at diagnosis. These findings indicate that lifestyle assessment near the time of breast cancer diagnosis identifies patients that could benefit from personalized dietary interventions to optimize prognostic factors such as BMI.
Citation Format: Bethina Liu, Sherry Shen, Erica Salehi, Yuan Chen, Nicolas Toumbacaris, Johnny Allsop, Cara Anselmo, Stacie Corcoran, Bridget Kelly, Rocco Magnoli, Andrea Smith, Melissa Emerzian, Julia Brockway-Marchello, Doreen Bacotti, Mark E. Robson, Neil M. Iyengar. Dietary patterns among women with early-stage breast cancer from the Healthy Living Program [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-08-07.
Collapse
Affiliation(s)
| | | | | | - Yuan Chen
- 4Memorial Sloan Kettering Cancer Center
| | | | | | | | | | | | | | | | | | | | | | | | - Neil M. Iyengar
- 16Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
6
|
Dempsey S, R Alijshi R, Corcoran S, Curley A. A Guide for Clinicians supporting Women and Families navigating Surrogacy. Ir Med J 2023; 116:731. [PMID: 37555787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 08/10/2023]
|
7
|
Bamford T, Easter C, Montgomery S, Smith R, Coomarasamy A, Smith RD, Young S, Anna B, Iasonos R, Louise B, Gina A, Wachter A, Corcoran S, Amy B, Alison C. A morphokinetic ploidy prediction model built and validated on over 8000 blastocysts. Reprod Biomed Online 2022. [DOI: 10.1016/j.rbmo.2022.08.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
8
|
Best L, Corcoran S, Armstrong E, Page A, Montgomery S, Nice L, Berrisford K, Drezet C, Lodge Y, Campbell A. A retrospective assessment of outcomes according to the concentration of protein in culture medium following vitrified oocyte warming. Reprod Biomed Online 2022. [DOI: 10.1016/j.rbmo.2022.08.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2022]
|
9
|
Rowed K, Shen S, Corcoran S, Clayton J, Kelly B, Smith A, Emerzian M, Cruz C, Robson M, Iyengar N. The Optimal Living Program: Integrating Exercise Into Cancer Care. Med Sci Sports Exerc 2022. [DOI: 10.1249/01.mss.0000876056.61076.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
10
|
Ryan GA, Finnegan C, McAuliffe FM, Malone FD, Müllers SM, Corcoran S, Mulcahy C, Dalrymple J, Donnelly J, Walsh J, Mcparland P, Martin A, Carroll S, Kent E. Fetoscopic Laser Ablation for Twin-to-Twin Transfusion Syndrome: A 15-year Review of Perinatal Survival. Ir Med J 2022; 115:595. [PMID: 35696199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective Twin to twin transfusion syndrome (TTTS) complicates 5-15% of monochorionic twin pregnancies and untreated is associated with a 90% mortality rate. The aim was to present the perinatal survival of patients with TTTS treated with laser ablation, by a national fetal medicine team. Methods This was a review of all cases of TTTS treated with fetoscopic laser ablation performed from March 2006 through to December 2020. All patients treated with fetoscopic laser were identified from the hospital database. The perinatal outcomes for the overall cohort and the individual Quintero stages were determined. Results A total of 155 cases of TTTS underwent fetoscopic laser ablation during the study period. The median gestational age at diagnosis was 19+1 weeks, with a mean growth discordance of 23.6%. The Quintero stage at diagnosis was: Stage 1 6.5% (10/155), Stage 2 49% (76/155), Stage 3 38.7% (60/155), Stage 4 5.8% (9/155). There was at least one survivor in 83.2% (129/155) of pregnancies, with dual survival in 52.9% (82/155). An increase in the rate of any survivor was observed from 75% (2006-2014) to 94% (2014-2020) (p<0.05). Dual survival decreased with increasing Quintero Stage (p<0.05). 80.6% (125/155) of pregnancies delivered prior to 34+6 weeks gestation. Conclusion Fetoscopic laser ablation is the recommended first line treatment for severe TTTS. We observed a survival rate of at least one twin in 83.2% pregnancies which is comparable to internationally published data on single-centre outcomes.
Collapse
Affiliation(s)
- G A Ryan
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
- UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland
| | - C Finnegan
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland
- Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland
| | - F M McAuliffe
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
- UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland
| | - F D Malone
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland
- Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland
| | - S M Müllers
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland
| | - S Corcoran
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
- UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland
| | - C Mulcahy
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
| | - J Dalrymple
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland
| | - J Donnelly
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland
- UCD Obstetrics & Gynaecology, University College Dublin, Ireland
| | - J Walsh
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
- UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland
| | - P Mcparland
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
- UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland
| | - A Martin
- UCD Obstetrics & Gynaecology, University College Dublin, Ireland
- Department of Obstetrics and Gynaecology, The Coombe Women And Infants University Hospital, Dublin, Ireland
| | - S Carroll
- Department of Obstetrics and Gynaecology, The National Maternity Hospital, Dublin, Ireland
| | - E Kent
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland
| |
Collapse
|
11
|
Bliss JW, Lavery JA, Underwood WP, Chun SS, Fickera GA, Lee CP, Corcoran S, Maloy MA, Polubriaginof FC, Kelly DW, Scott JM, Boutros PC, Moskowitz CS, Jones LW. Impact of Exercise on Susceptibility and Severity of COVID-19 in Patients with Cancer: A Retrospective Study. Cancer Epidemiol Biomarkers Prev 2022; 31:1036-1042. [PMID: 35506245 DOI: 10.1158/1055-9965.epi-21-1186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 11/30/2021] [Accepted: 02/22/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Modifiable lifestyle-related factors heighten the risk and severity of coronavirus disease 2019 (COVID-19) in patients with cancer. Whether exercise lowers susceptibility or severity is not known. METHODS We identified 944 cancer patients from Memorial Sloan Kettering Cancer Center (mean age: 64; 85% female; 78% White) completing an exercise survey before receiving a confirmed positive or negative SARS-CoV-2 test. Exercise was defined as reporting moderate-intensity ≥5 days per week, ≥30 minutes/session or strenuous-intensity ≥3 days per week, ≥20 minutes/session. Multivariable logistic regression was used to determine the relationship between exercise and COVID-19 susceptibility and severity (i.e., composite of hospital admission or death events) with adjustment for clinical-epidemiologic covariates. RESULTS Twenty-four percent (230/944) of the overall cohort were diagnosed with COVID-19 and 35% (333/944) were exercisers. During a median follow-up of 10 months, 26% (156/611) of nonexercising patients were diagnosed with COVID-19 compared with 22% (74/333) of exercising patients. The adjusted OR for risk of COVID-19 was 0.65 [95% confidence interval (CI), 0.44-0.96, P = 0.03] for exercisers compared with nonexercisers. A total of 20% (47/230) of COVID-19 positive patients were hospitalized or died. No difference in the risk of severe COVID-19 as a function of exercise status was observed (P > 0.9). CONCLUSIONS Exercise may reduce the risk of COVID-19 infection in patients with a history of cancer, but not its severity. IMPACT This study provides the first data showing that exercise might lower the risk of COVID-19 in cancer patients, but further research is required.
Collapse
Affiliation(s)
- Joshua W Bliss
- New York Presbyterian - Weill Cornell Medicine, New York, New York
| | | | | | - Su S Chun
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Gina A Fickera
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | | | - Molly A Maloy
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Daniel W Kelly
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jessica M Scott
- New York Presbyterian - Weill Cornell Medicine, New York, New York.,Memorial Sloan Kettering Cancer Center, New York, New York
| | - Paul C Boutros
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, California.,Department of Medical Biophysics, University of Toronto, Toronto, Canada.,Institute for Precision Health, University of California, Los Angeles, Los Angeles, California.,Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
| | - Chaya S Moskowitz
- New York Presbyterian - Weill Cornell Medicine, New York, New York.,Memorial Sloan Kettering Cancer Center, New York, New York
| | - Lee W Jones
- New York Presbyterian - Weill Cornell Medicine, New York, New York.,Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
12
|
Shen S, Allsop J, Salehi E, Anselmo C, Corcoran S, Clayton J, Smith A, Emerzian M, Robson M, Iyengar N. Abstract P1-09-05: Baseline dietary patterns among women with newly diagnosed early-stage breast cancer enrolled in the Optimal Living Program. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p1-09-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Evidence-based recommendations support a dietary pattern rich in whole grains, fruits, and vegetables with limited consumption of added sugars to improve cancer risk and mortality. The Optimal Living Program (OLP) is a prospective multiparametric lifestyle intervention that engages early-stage breast cancer patients at the time of diagnosis in risk-stratified, personalized lifestyle management. Here, we report baseline dietary patterns among women enrolled in the OLP. Methods: Upon enrollment, patients complete a questionnaire that incorporates the National Cancer Institute (NCI) Dietary Screener Questionnaire (DSQ), which queries the consumption frequency of 26 food items over the past month. Based on standard NCI DSQ scoring procedures, we calculated total daily serving equivalents of all food items within a dietary factor group. This included: 1) total daily cup equivalents of fruit and vegetables from fruit, fruit juice, salad, potatoes, beans, other vegetables, tomato sauce, salsa, and pizza, 2) total daily ounce equivalents per day of whole grains from cereal, whole grain bread, popcorn, and whole grain rice, and 3) total daily teaspoon (tsp) equivalents of added sugars from cookies/cake/pie, doughnuts, ice cream, candy, cereals, and sugar-sweetened beverages including soda, fruit drinks, and sugar/honey in coffee/tea. Results: There were 100 patients enrolled in the OLP for whom baseline DSQ data were available. The median age at diagnosis was 58 and median BMI was 27.4 mg/m2. 69 patients were white (69.0%), 14 were Black (14.0%), and 7 were Asian (7.0%). 62 patients had stage I disease (62.0%), 22 patients had stage II disease (22.0%), and 15 patients had ductal carcinoma in situ (15.0%). 74 patients had hormone receptor-positive disease (74.0%), 3 had HER2-positive disease (3.0%), and 7 had triple-negative disease (7.0%). Daily frequency of consumption of dietary factor groups are shown in Table 1. Only 29 patients (29.0%) met the current dietary guideline of 4-5 cup equivalents of fruits and vegetables per day and no patients (0%) met the guideline of more than 3 ounce equivalents of whole grains per day. Added sugar intake ranged from 0 to 4.8 teaspoon equivalents per day. Conclusion: Most women in this cohort with newly diagnosed early-stage breast cancer did not consume the recommended daily intake of fruits, vegetables, and whole grains per the 2020-2025 Dietary Guidelines and the American Institute for Cancer Research. Our findings identify these dietary factors as important targets of intervention with personalized dietary guidance at the time of breast cancer diagnosis.
Table 1.<1/day1 - 2/day2 - 3/day3 – 4/day>4/dayFruits and vegetables (cup equivalents)6 (6.0%)23 (23.0%)28 (28.0%)14 (14.0%)29 (29.0%)Whole grains (ounce equivalents)63 (63.0%)29 (29.0%)8 (8.0%)0 (0%)0 (0%)Added sugar (tsp equivalents)32 (32.0%)35 (35.0%)22 (22.0%)6 (6.0%)5 (5.0%)Sugar-sweetened beverages (tsp equivalents)62 (62.0%)21 (21.0%)15 (15.0%)2 (2.0%)0 (0%)
Citation Format: Sherry Shen, Johnny Allsop, Erica Salehi, Cara Anselmo, Stacie Corcoran, Jill Clayton, Andrea Smith, Melissa Emerzian, Mark Robson, Neil Iyengar. Baseline dietary patterns among women with newly diagnosed early-stage breast cancer enrolled in the Optimal Living Program [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-09-05.
Collapse
Affiliation(s)
- Sherry Shen
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Johnny Allsop
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Erica Salehi
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Cara Anselmo
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Jill Clayton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Andrea Smith
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Mark Robson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Neil Iyengar
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
13
|
Corcoran S, Licciardi F, Weber E, Duggan E, Woodside A, Correa Z, lachaud-Richard M, Kassa A, Jakubowski AA. Improving referrals to survivorship: A patient-driven initiative. J Clin Oncol 2021. [DOI: 10.1200/jco.2020.39.28_suppl.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
44 Background: Patients often feel lost in the transition from cancer patient to survivor. As cancer treatment improves, the number of survivors in the US is expected to approach 22 million by the year 2029. Smaller increases in the MD workforce coupled with long-term effects of new treatments necessitate the creation survivorship clinics led by advanced practice providers (APP) who are disease-specialized and specifically trained to manage unique survivor needs. Although the institutions Survivorship program was established more than a decade ago, the average referral rate to the program is only 30%. Given the high levels of patient satisfaction with the program, we sought to understand and address clinician awareness and referral obstacles. Methods: Based on patient input, members of our Patient & Family Advisory Council for Quality (PFACQ) put forth a proposal aimed at increasing referrals to the Survivorship program. A multidisciplinary working group comprising patients, clinicians, administrators and process engineers was assembled. Process Improvement training was conducted, and a primary goal was developed: increase Survivorship referrals by 25%. Central to the approach was engagement with referring physicians and APPs on a service-by-service basis. A four-question survey was developed to address timing of initial discussion, challenges to referring, knowledge of visit elements, and materials needed to support referrals. A customized ‘roadshow’ presentation was created and delivered by a PFACQ member at a faculty meeting. Highlights included: the importance of Survivorship care to patients and details of the visit, survey responses, and additional faculty discussion and input. Results: Four roadshows were completed from August 2020-June 2021: Gynecologic Surgery, Endocrine, Breast Medicine and Lymphoma. Based on survey responses and dialogue with providers, new material to support patient discussions and education have been developed: a patient-facing brochure, clinician- & patient-facing video, and clinician talking points. Methods to facilitate identifying eligible patients were also discussed, as well as automatic referrals to Survivorship for selected services. Data reveal a significant increase in referral rates from GYN and Endocrine services (follow up > 6 months) of 63% and 228%, respectively. (Breast Medicine and Lymphoma with shorter follow up will be reported.) Engagement with other services is underway. Conclusions: Results have exceeded the goal of increasing referral rates to the program. This process suggests that ongoing engagement with referring clinicians is essential to achieving and maintaining higher referral rates. The patient voice throughout this process has been a powerful tool in raising clinician awareness of their experiences and expectations for comprehensive follow up care, which can be delivered on a greater scale by survivorship providers.
Collapse
Affiliation(s)
| | - Frank Licciardi
- MSKCC Patient & Family Advisory Council for Quality (PFACQ), New York, NY
| | - Eliza Weber
- MSKCC Patient & Family Advisory Council for Quality (PFACQ), New York, NY
| | - Erika Duggan
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | - Alyse Kassa
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | |
Collapse
|
14
|
Corcoran S, Corcoran D, Wachter A, Andrews E, Campbell J, Delphine D, Kuczera B, Campbell A. P–253 Description of a rare spontaneous monozygotic blastocyst splitting into two discrete euploid blastocysts in vitro detected with time-lapse imaging and preimplantation genetic testing (PGT). Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Can spontaneous and complete blastocyst splitting into two, in vitro, be investigated using time-lapse imaging and biopsy of each trophectoderm, for inference of ploidy?
Summary answer
Time-lapse imaging combined with PGT-A gives insights into the incidence, dynamics and timing of rare blastocyst splitting and the ploidy status of each resulting blastocyst.
What is known already
It is well known that multiple births occur more often with Assisted Reproductive Technologies (ART) than spontaneous conception, even after single embryo transfer. The mechanism of Monozygotic Twinning (MZT) during ART is still unclear but cryopreservation, extended culture, PGT, maternal age and assisted hatching are reported risk factors. MZT is a rare phenomenon, with an incidence of 0.4% in natural conception compared with up to 4.9% in ART. The timing of embryo splitting dictates the type of twinning, in terms of chorionicity and amnionicty, and this is officially determined using ultrasound scanning.
Study design, size, duration
This is a case study describing the detection of the complete splitting of an IVF blastocyst at 140 hours post insemination (hpi), using time-lapse imaging.
The 40-year-old patient previously experienced biochemical pregnancy and several miscarriages; an ectopic molar pregnancy and a probable cornual ectopic. The 39-year-old male partner was normozoospermic.
Participants/materials, setting, methods
Facilitative laser breaching was performed, according to standard operating procedure, of the morula at 96hpi of embryo development, prior to PGT. Images were collected every 10 minutes and developmental events and embryos morphology annotated using the EmbryoScope+™ time lapse incubator and software.
Main results and the role of chance
Over 50,000 hatching blastocysts have been time-lapse imaged, scrutinised and annotated within this group of fertility clinics. This is the first time that such a rare blastocyst splitting event has been recorded and studied.
Following observation of two pronuclei following IVF and typical cleavage development to blastocyst, with facilitative zona breaching on, at 106.7hpi, the full blastocyst’s trophectoderm (TE) began to herniate and hatch. By 114.3hpi a second internal blastocoel cavity formed appearing to divide the inner cell mass (ICM) within the zona pellucida (ZP). This resulting blastocyst proceeded to hatch as its discrete ICM migrated out of the ZP, along with its TE. TE cells from the original blastocyst then began to hatch at 117.5hpi at the same breached site in the ZP with its ICM visibly evacuating the ZP.
By 140hpi the blastocyst had split into two discrete blastocysts while hatching from the ZP. Both resulting blastocysts had clear and separate ICMs and TEs present. Biopsy of approximately 5 cells was performed for each TE, and the blastocysts were vitrified individually. Next Generation Sequencing (NGS) reported both blastocysts to be euploid.
Limitations, reasons for caution
This case may have been detectable without time-lapse imaging, as the splitting was completed prior to biopsy. More expert scrutiny of the images may result in earlier signs of twinning in progress being detected.
Wider implications of the findings: The nature of this detectable in vitro blastocyst splitting, indicates these embryos (if they implanted) to be monozygotic, dichoriol-diamniotic ‘identical’ twins. However – as single embryo transfer is the preferred treatment plan; they may be born years apart. These observations could shed light on the debated models of monozygotic twinning.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- S Corcoran
- Beacon CARE Fertility Clinic, Laboratory, Dublin, Ireland
| | - D Corcoran
- Beacon CARE Fertility Clinic, Laboratory, Dublin, Ireland
| | - A Wachter
- Beacon CARE Fertility Clinic, Laboratory, Dublin, Ireland
| | - E Andrews
- Beacon CARE Fertility Clinic, Laboratory, Dublin, Ireland
| | - J Campbell
- Beacon CARE Fertility Clinic, Laboratory, Dublin, Ireland
| | - D Delphine
- Beacon CARE Fertility Clinic, Laboratory, Dublin, Ireland
| | - B Kuczera
- Beacon CARE Fertility Clinic, Clinical, Dublin, Ireland
| | - A Campbell
- CARE Fertility Group, Director of Embryology, Manchester, United Kingdom
| |
Collapse
|
15
|
Choi JW, Corcoran S, Wang B, Häupl B, Ceribelli M, Huang DW, Wright GW, Shaffer AL, Phelan JD, Scheich S, Yu X, Yang Y, Thomas C, Oellerich T, Staudt LM. TARGETING PROXIMAL BCR SIGNALING PATHWAY IN DIFFUSE LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.11_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. W Choi
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - S Corcoran
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - B Wang
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - Björ Häupl
- Goethe University Department of Medicine II, Hematology/Oncology Frankfurt Germany
| | - M Ceribelli
- National Center for Advancing Translational Sciences Division of Preclinical Innovation Gaithersburg USA
| | - D. W Huang
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - G. W Wright
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - A. L Shaffer
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - J. D Phelan
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - S Scheich
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - X. Yu
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - Y Yang
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| | - C Thomas
- National Center for Advancing Translational Sciences Division of Preclinical Innovation Gaithersburg USA
| | - T Oellerich
- Goethe University Department of Medicine II, Hematology/Oncology Frankfurt Germany
| | - L. M Staudt
- National Cancer Institute Lymphoid Malignancy Branch Bethesda USA
| |
Collapse
|
16
|
Jimenez‐Kurlander L, Antal Z, DeRosa A, Diotallevi D, Pottenger E, Wilson N, Corcoran S, Boulad F, Friedman DN. COVID-19 in pediatric survivors of childhood cancer and hematopoietic cell transplantation from a single center in New York City. Pediatr Blood Cancer 2021; 68:e28857. [PMID: 33355979 PMCID: PMC7883208 DOI: 10.1002/pbc.28857] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 12/04/2020] [Accepted: 12/06/2020] [Indexed: 12/14/2022]
Abstract
Childhood cancer survivors are at increased risk for treatment-related late effects; data are lacking on how coronavirus disease 2019 (COVID-19) infection impacts this cohort. We assessed COVID-19-related symptoms, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG seroprevalence, and rate of COVID-19-related hospitalization among 321 asymptomatic survivors of childhood cancer or transplantation seen for routine long-term follow-up between May and September 2020 in a New York City tertiary cancer center. While 10.9% (n = 35) reported possible COVID-19-related symptoms, 7.8% (n = 20) of those tested had positive SARS-CoV-2 IgG, and one patient (0.3%) required COVID-19-related hospitalization. This report suggests that childhood cancer survivors appear to be at relatively low risk for COVID-19 complications.
Collapse
Affiliation(s)
| | - Zoltan Antal
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York,Weill Cornell Medical CollegeNew YorkNew York
| | - Amelia DeRosa
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York
| | - Deborah Diotallevi
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York
| | - Elaine Pottenger
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York
| | - Nadia Wilson
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York
| | - Stacie Corcoran
- Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkNew York
| | - Farid Boulad
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York,Weill Cornell Medical CollegeNew YorkNew York
| | - Danielle Novetsky Friedman
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkNew York,Weill Cornell Medical CollegeNew YorkNew York
| |
Collapse
|
17
|
Corcoran S, Russell J, Clayton J, Smith A, Keenan K, Robson M, Iyengar N. Abstract PS9-04: The optimal living and survivorship program: Piloting a novel cancer survivorship care model. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps9-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Multiple national agencies define cancer survivorship as beginning at the time of cancer diagnosis. However, traditional care models typically deliver “survivorship care” months or years after diagnosis, which can lead to disruption in care and “transition anxiety”. We hypothesized that an approach centered around wellbeing could be applied across the cancer continuum (starting at diagnosis) and serve as a novel survivorship care model.
Methods: We developed the Optimal Living and Survivorship Program, a novel telehealth platform that is designed to better engage cancer survivors by providing multidisciplinary and individualized lifestyle management during and after cancer therapy. Our multilevel approach relies on three key components: 1) a digitized centralized model that provides automated and coordinated multidisciplinary care; 2) an individualized Wellness Plan (WP); and 3) enrollment at the time of cancer diagnosis in order to mitigate the experience of post-treatment transition. Participants complete a digital wellness questionnaire (WQ) consisting of validated instruments that provide risk assessment for a broad range of lifestyle and psychosocial factors prior to the first medical oncology consult, receive a validated algorithm-based WP reviewed by a Wellness Coordinator, and meet with a specially trained Wellness Advanced Practice Provider (WAPP) via tele-medicine. The WP consists of individualized topic-specific educational materials (e.g., webinars, videos) and referrals to indicated supportive services (e.g., nutrition, exercise physiology, financial counseling, integrative medicine). The WAPP will ultimately assume care of the patient in the post-treatment (“survivorship”) phase. We piloted this approach in patients diagnosed with breast cancer beginning in November 2019. The primary outcome is feasibility defined by completion of the WQ. Secondary outcomes include participation in the WAPP visits, attendance at referral appointments, and quality of life (QOL).
Results: As a result of COVID-19, the pilot was paused in February 2020. Data collected from November 2019 through February 2020 reveal a total of 67 eligible patients with newly diagnosed breast cancer were approached, with 65 (97%) enrolled in the program. All participants completed the WQ and all received a WP with indicated supportive referrals and educational resources. All participants engaged partially or fully with WP recommendations. Participants were screened at high risk for an average of 3.8 unmet needs, and 98% were at high risk for 2 or more needs at the time of diagnosis. Exercise was identified as the highest unmet need (83%). There was 76% adherence with referral to the program’s Exercise Physiologist. Other commonly identified areas of needs were nutrition (59%) and sleep quality (51%). WAPP tele-medicine visits began in June 2020 and are ongoing; visit completion rates and interventions will be presented. Qualitative data regarding patient experience and QOL will be obtained via focused interviews and feedback will be categorized in thematic domains.
Conclusions: In this pilot, the majority of patients with newly diagnosed breast cancer enrolled in the program, completed a WQ in advance of their initial medical oncology visit, and engaged with the WP. Our findings suggest that this early introduction to survivorship care is feasible. Earlier patient engagement and incorporation of wellness and supportive services from time of diagnosis may significantly improve our ability to address multifactorial needs during and after cancer therapy.
Citation Format: Stacie Corcoran, John Russell, Jill Clayton, Andrea Smith, Kate Keenan, Mark Robson, Neil Iyengar. The optimal living and survivorship program: Piloting a novel cancer survivorship care model [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-04.
Collapse
Affiliation(s)
| | - John Russell
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jill Clayton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Andrea Smith
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Kate Keenan
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Mark Robson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Neil Iyengar
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
18
|
Corcoran S, Russell J, Clayton J, Kelly B, Smith A, Keenan K, Robson ME, Iyengar NM. The optimal living and survivorship program: Piloting a novel survivorship care model. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.29_suppl.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
40 Background: Multiple agencies define cancer survivorship as beginning at the time of diagnosis. However, traditional care models deliver “survivorship care” months or years after diagnosis, which can cause care disruption and “transition anxiety”. We hypothesized that an approach centered around wellbeing could be applied across the cancer continuum (starting at diagnosis) and serve as a novel survivorship care model. Methods: We developed the Optimal Living and Survivorship Program with 3 key components: 1) a centralized model that provides multidisciplinary care; 2) an individualized Wellness Plan (WP); and 3) enrollment at the time of diagnosis to mitigate post-treatment transition. Participants complete a digital wellness questionnaire (WQ) prior to the 1st medical oncology consult, receive a validated algorithm-based WP, and meet with a Wellness Advanced Practice Provider (WAPP). The WP consists of individualized education and referrals (e.g., nutrition, exercise, financial counseling). The WAPP will assume post-treatment (“survivorship”) care. We piloted this approach in patients diagnosed with breast cancer beginning in 11/19. The primary outcome is feasibility defined by completion of the WQ. Secondary outcomes include participation in the WAPP visits, attendance at appointments, and quality of life (QOL). Results: Due to COVID-19, the pilot was paused in 2/20. Data collected from 11/19 through 2/20 reveal a total of 67 eligible patients with newly diagnosed breast cancer were approached, with 65 enrolled. All participants completed the WQ and all received a WP with supportive referrals and educational resources. All participants engaged with WP recommendations. Participants were screened at high risk for an average of 3.8 unmet needs, and 98% were at high risk for 2 or more needs at time of diagnosis. Exercise was the highest unmet need (83%). There was 76% adherence with referral to the program’s Exercise Physiologist. Other areas of needs were nutrition (59%) and sleep quality (51%). WAPP tele-visits began in 6/20; visit completion rates will be presented. Qualitative data regarding patient experience and QOL will be obtained via interviews and feedback will be categorized in thematic domains. Conclusions: Most patients enrolled in the program, completed a WQ and engaged with the WP. Our findings suggest that this early intro to survivorship is feasible. Earlier engagement and incorporation of wellness and supportive services from time of diagnosis may improve our ability to address multifactorial needs during and after cancer therapy.
Collapse
Affiliation(s)
| | - John Russell
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jill Clayton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Bridget Kelly
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Andrea Smith
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | - Neil M. Iyengar
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
19
|
Abstract
e14038 Background: Patient-reported outcomes (PRO) offer insight into patient perception of health and symptom burden. Despite a shift toward electronic PRO (ePRO), optimal administration methods are unclear. Our institution recently began ePRO collection in survivorship clinics: patients are invited via email to complete a health survey on our online patient portal prior to annual visits, enabling clinician review of symptoms in advance of the visit. Patients who do not complete an ePRO survey at home are offered an iPad or paper survey at visit check-in. In the first year of ePRO, 87 patients inadvertently submitted multiple responses to the questionnaire, across two modalities. This study aimed to 1) assess determinants of ePRO completion across modalities (portal, iPad, paper); and, 2) among patients who submitted multiple surveys, compare consistency of responses in surveys completed within 30 days of each other. Methods: We reviewed records for 10194 patients seen in breast, thoracic, colorectal, and gynecologic survivorship clinics over one year. Demographics, disease/treatment details, and PRO responses (symptoms, health behaviors, etc.) were extracted. For aim 1, we used multivariate regression to determine predictors of completion method. For aim 2, we calculated Cohen’s kappa coefficients to compare responses based on completion modality. Results: Most patients (65.6%) completed the survey on an iPad in clinic; 16.7% on the portal, 17.7% on paper in clinic. Younger age (p < .001), white race (p < .001), less fatigue (p = .01), and English as primary language (p < .001) were associated with portal use in multivariate analyses. In general, Cohen’s Kappa analyses revealed high agreement between surveys. Conclusions: Our findings highlight demographic gaps in ePRO acceptance. Although most patients completed an ePRO (portal or iPad), few completed it at home in advance of their visit, which has implications for clinic flow and clinician preparation for visits. However, our finding of consistent symptom reporting across mode and location of completion is reassuring. Future work should seek to improve comfort with ePRO completion at home among groups less likely to accept it and explore the implications of symptom burden on ePRO acceptance.
Collapse
|
20
|
Corcoran S, Russell J, Smith A, Kelly B, Clayton J, Stein B, Keenan K, Robson ME, Iyengar NM. The optimal living and wellness program: Piloting a novel survivorship care model. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e14003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14003 Background: Multiple national agencies define cancer survivorship as beginning at the time of cancer diagnosis. However, traditional care models deliver “survivorship care” months or years after diagnosis, which can lead to disruption in care and “transition anxiety”. We hypothesized that an approach centered around wellbeing could be applied across the cancer continuum (starting at diagnosis) and serve as a novel survivorship care model. Methods: We developed the Optimal Living and Wellness Program, a multilevel intervention with 3 key components: 1) a centralized model that provides coordinated multidisciplinary care; 2) an individualized Wellness Plan (WP); and 3) enrollment at the time of cancer diagnosis in order to mitigate the experience of post-treatment transition. Participants complete a digital wellness questionnaire (WQ) prior to the first medical oncology consult, receive a validated algorithm-based WP reviewed by a Wellness Coordinator, and meet with a Wellness Advanced Practice Provider (WAPP) via tele-medicine. The WP consists of individualized education and referrals to indicated supportive services (e.g., nutrition, exercise physiology, financial counseling, integrative medicine). The WAPP will ultimately assume care of the patient in the post-treatment (“survivorship”) phase. We piloted this approach in patients diagnosed with breast cancer beginning in November 2019. The primary outcome is feasibility defined by completion of the WQ. Secondary outcomes include participation in the WAPP visits, attendance at referral appointments, and quality of life (QOL). Results: As of January 31, 2020, a total of 39 eligible patients with newly diagnosed breast cancer were approached. Of these, 36 (92%) have completed the WQ. All 36 participants received a WP with indicated supportive referrals and educational resources. Initial WAPP tele-visits will begin in May 2020. Qualitative data regarding patient experience and QOL will be obtained via focused interviews and feedback will be categorized in thematic domains. Conclusions: In this pilot, the majority of patients with newly diagnosed breast cancer completed a WQ in advance of their initial medical oncology visit, indicating preliminary feasibility. Patient enrollment is ongoing, and updated data including additional feasibility metrics and QOL will be presented. Earlier patient engagement and incorporation of wellness and supportive services from time of diagnosis may significantly improve the transition to post-treatment care.
Collapse
Affiliation(s)
| | - John Russell
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Andrea Smith
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Bridget Kelly
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jill Clayton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Bennet Stein
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | - Neil M. Iyengar
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
21
|
Egan SA, Corcoran S, McDermott H, Fitzpatrick M, Hoyne A, McCormack O, Cullen A, Brennan GI, O'Connell B, Coleman DC. Hospital outbreak of linezolid-resistant and vancomycin-resistant ST80 Enterococcus faecium harbouring an optrA-encoding conjugative plasmid investigated by whole-genome sequencing. J Hosp Infect 2020; 105:726-735. [PMID: 32439548 DOI: 10.1016/j.jhin.2020.05.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 05/11/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Linezolid is an antibiotic used to treat infections caused by multi-drug-resistant Gram-positive bacteria. Linezolid resistance in enterococci has been reported with increasing frequency, with a recent rise in resistance encoded by optrA, poxtA or cfr. AIM To investigate a hospital outbreak of linezolid- and vancomycin-resistant Enterococcus faecium (LVREfm) using whole-genome sequencing (WGS). METHODS Thirty-nine VREfm from patient screening (19 isolates, 17 patients) and environmental sites (20 isolates) recovered in October 2019 were investigated. Isolates were screened using polymerase chain reaction for optrA, poxtA and cfr, and underwent Illumina MiSeq WGS. Isolate relatedness was assessed using E. faecium core genome multi-locus sequence typing (cgMLST). One LVREfm underwent MinION long-read WGS (Oxford Nanopore Technologies) and hybrid assembly with MiSeq short-read sequences to resolve an optrA-encoding plasmid. FINDINGS Twenty isolates (51.3%) were LVREfm and optrA-positive, including the LVREfm from the index patient. A closely related cluster of 28 sequence type (ST) 80 isolates was identified by cgMLST, including all 20 LVREfm and eight linezolid-susceptible VREfm, with an average allelic difference of two (range 0-10), indicating an outbreak. Nineteen (95%) LVREfm harboured a 56,684-bp conjugative plasmid (pEfmO_03). The remaining LVREfm exhibited 44.1% sequence coverage to pEfmO_03. The presence of pEfmO_03 in LVREfm and the close relatedness of the outbreak cluster isolates indicated the spread of a single strain. The outbreak was terminated by enhanced infection prevention and control (IPC) and environmental cleaning measures, ceasing ward admissions and ward-dedicated staff. CONCLUSION WGS was central in investigating an outbreak of ST80 LVREfm. The rapid implementation of enhanced IPC measures terminated the outbreak.
Collapse
Affiliation(s)
- S A Egan
- Microbiology Research Unit, Division of Oral Biosciences, Dublin Dental University Hospital, University of Dublin, Trinity College, Dublin, Ireland
| | - S Corcoran
- Department of Clinical Microbiology, Bon Secours Hospital Dublin, Glasnevin, Dublin, Ireland
| | - H McDermott
- Department of Clinical Microbiology, Bon Secours Hospital Dublin, Glasnevin, Dublin, Ireland
| | - M Fitzpatrick
- Infection Prevention and Control Department, Bon Secours Hospital Dublin, Glasnevin, Dublin, Ireland
| | - A Hoyne
- Department of Clinical Microbiology, Bon Secours Hospital Dublin, Glasnevin, Dublin, Ireland
| | - O McCormack
- Department of Clinical Microbiology, Bon Secours Hospital Dublin, Glasnevin, Dublin, Ireland
| | - A Cullen
- Pharmacy Department, Bon Secours Hospital Dublin, Glasnevin, Dublin, Ireland
| | - G I Brennan
- National MRSA Reference Laboratory, St. James's Hospital, Dublin, Ireland
| | - B O'Connell
- National MRSA Reference Laboratory, St. James's Hospital, Dublin, Ireland; Department of Clinical Microbiology, School of Medicine, University of Dublin, Trinity College, St. James's Hospital, Dublin, Ireland
| | - D C Coleman
- Microbiology Research Unit, Division of Oral Biosciences, Dublin Dental University Hospital, University of Dublin, Trinity College, Dublin, Ireland.
| |
Collapse
|
22
|
Abstract
89 Background: The number of cancer survivors in the United States is expected to approach 22 million by the year 2029. With an annual Survivorship Program visit volume exceeding 16,000, this comprehensive cancer center developed an innovative approach to delivering survivorship care to meet the growing demand for comprehensive follow up care. Institutional space, patient convenience and visit compliance are also factors in considering alternatives to traditional ‘brick and mortar’ visits. Methods: Patients are seen in our Autologous Bone Marrow Transplant (BMT) Survivorship Clinic at 6, 12- and 24-months post-transplant. A pilot was developed targeting patients scheduled for a 6-month visit, where patients are often struggling with treatment sequelae, managing other medical appointments, and returning to work and life after transplant. Patients were offered a telemedicine visit instead of an in-person clinic visit with the survivorship advanced practice provider (APP). The Survivorship APP and administrative staff were trained on the use of monitors and technologic means to connect patient to provider. Eligible patients had to have an institutional portal account and speak English. They were contacted by phone to assess interest, and if they agreed, instructions were provided via secure institutional portal reviewing device and connectivity requirements. Results: The telemedicine visit components included: review of home medication list, interval history and review of systems, screen for late treatment effects, lab result review, treatment summary and care plan review including risk of secondary cancer and screening recommendations, health promotion counseling, primary care physician recommendations and immunization status. Of 26 visits scheduled, 22 were successfully completed. Challenges to completing the visit will be described and include poor connectivity and patient location at the time of the scheduled visit. Conclusions: Despite some minor challenges, patients described good satisfaction with telemedicine citing visit comprehensiveness and convenience. As a result of the successful pilot, telemedicine visits are being expanded to include survivorship patients who are 24 months post BMT.
Collapse
|
23
|
Salz T, Schnall RB, McCabe MS, Oeffinger KC, Corcoran S, Vickers AJ, Salner AL, Dornelas E, Raghunathan NJ, Fortier E, McKiernan J, Finitsis DJ, Chimonas S, Baxi S. Incorporating Multiple Perspectives Into the Development of an Electronic Survivorship Platform for Head and Neck Cancer. JCO Clin Cancer Inform 2019; 2:1-15. [PMID: 30652547 DOI: 10.1200/cci.17.00105] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
PURPOSE To improve the care of survivors of head and neck cancer, we developed the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR). HN-STAR is an electronic platform that incorporates patient-reported outcomes into a clinical decision support tool for use at a survivorship visit. Selections in the clinical decision support tool automatically populate a survivorship care plan (SCP). We aimed to refine HN-STAR by eliciting and incorporating feedback on its ease of use and usefulness. METHODS Human-computer interaction (HCI) experts reviewed HN-STAR using think-aloud testing and the Nielsen Heuristic Checklist. Nurse practitioners (NPs) thought aloud while reviewing the clinical decision support tool and SCP and responded to an interview. Survivors used HN-STAR as part of a routine visit and were interviewed afterward. We analyzed themes from the feedback. We described how we addressed each theme to improve the usability of HN-STAR. RESULTS Five HCI experts, 10 NPs, and 10 cancer survivors provided complementary usability insight that we categorized into themes of improvements. For ease of use, themes included technical design considerations to enhance user interface, ease of completion of a self-assessment, streamlining text, disruption of the clinic visit, and threshold for symptoms to appear on the SCP. The theme addressing usefulness was efficiency and comprehensiveness of the clinic visit. For each theme, we report revisions to HN-STAR in response to the feedback. CONCLUSION HCI experts provided key technical design insights into HN-STAR, whereas NPs and survivors provided usability feedback and clinical perspectives. We incorporated the feedback into the preparation for additional testing of HN-STAR. This method can inform and improve the ease of use and usefulness of the survivorship applications.
Collapse
Affiliation(s)
- Talya Salz
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Rebecca B Schnall
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Mary S McCabe
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Kevin C Oeffinger
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Stacie Corcoran
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Andrew J Vickers
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Andrew L Salner
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Ellen Dornelas
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Nirupa J Raghunathan
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Elizabeth Fortier
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Janet McKiernan
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - David J Finitsis
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Susan Chimonas
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| | - Shrujal Baxi
- Talya Salz, Mary S. McCabe, Stacie Corcoran, Andrew J. Vickers, Nirupa J. Raghunathan, Elizabeth Fortier, Janet McKiernan, Susan Chimonas, and Shrujal Baxi, Memorial Sloan Kettering Cancer Center; Rebecca B. Schnall, Columbia University School of Nursing, New York, NY; Kevin C. Oeffinger, Duke University Medical Center, Durham, NC; Andrew L. Salner, Ellen Dornelas, and David J. Finitsis, Hartford HealthCare Cancer Institute, Hartford, CT; and Shrujal Baxi, Weill-Cornell School of Medicine, New York, NY
| |
Collapse
|
24
|
Kissick DJ, Martin-Garcia JM, Hu H, Venugopalan N, Xu S, Corcoran S, Ferguson D, Hilgart MC, Makarov O, Xu Q, Ogata C, Stepanov S, Thifault D, Marlowe T, Alvarado C, Zacks M, Cance W, Fromme P, Fischetti RF. Improvements in serial crystallography capabilities at GM/CA. Acta Crystallogr A Found Adv 2019. [DOI: 10.1107/s010876731909562x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
25
|
Thom B, Boekhout AH, Corcoran S, Adsuar R, Oeffinger KC, McCabe MS. Advanced Practice Providers and Survivorship Care: They Can Deliver. J Oncol Pract 2019; 15:e230-e237. [PMID: 30615587 DOI: 10.1200/jop.18.00359] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
INTRODUCTION As the number of cancer survivors grows, new models of survivorship care are being implemented, but there is limited evaluation to date. This retrospective review assesses the concordance of care provided to adult-onset cancer survivors by advanced practice providers (nurse practitioners and physician assistants) with Institute of Medicine guidelines for survivorship care. METHODS Records from three survivorship clinics at a single institution were reviewed for frequency of recurrence surveillance, screening for second cancers, symptom management (physical, psychological), health promotion education (alcohol, tobacco, cholesterol, and bone density screenings; diet/exercise discussion), care coordination, and provision of care plan. Data were characterized using descriptive statistics. RESULTS Over 2 years, 9,052 unique survivorship visits occurred; 210 breast, 208 prostate, and 204 colorectal visits were randomly selected for review. All patients with breast cancer underwent surveillance for recurrence; 99% were screened for new cancers. Discussion of health promotion activities ranged from 83% to 100%; 91% of patients were reviewed for physical symptoms, and 93% were reviewed for psychological symptoms. All patients with prostate cancer underwent recurrence surveillance; 97% were screened for new primaries. Health promotion activities ranged from 70% to 97%, and symptoms were discussed in 89% of visits. All patients with colorectal cancer underwent a surveillance colonoscopy for recurrence; 97% had a carcinoembryonic antigen test. Among women, 97% had mammograms, and 96% had a Papanicolaou test; 83% of men had a prostate-specific antigen test. Health promotion activities ranged from 69% to 100%, and symptoms were discussed in 93% to 97% of visits. CONCLUSIONS Findings suggest that advanced practice providers can provide survivorship care in accordance with Institute of Medicine standards, which provide a normative standard. This assessment is an important step in evaluating survivorship outcomes.
Collapse
Affiliation(s)
| | - Annelies H Boekhout
- 2 Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| | | | | | | | - Mary S McCabe
- 1 Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
26
|
Baxi SS, Sukhu R, Fortier E, Oeffinger K, Corcoran S, Salner A, Vickers AJ, McCabe MS, Salz T. Automating Treatment Summary Development Using Electronic Billing Information: A Pilot Study of Survivors of Head and Neck Cancer. J Oncol Pract 2018; 15:e84-e90. [PMID: 30523752 DOI: 10.1200/jop.18.00022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Although the provision of a treatment summary (TS) is a quality indicator in oncology, routine delivery of TSs remains challenging. Automatic TS generation could facilitate use, but data on accuracy are lacking in complex cancers such as head and neck cancer (HNC). We developed and evaluated an electronic platform to automate TS generation for HNC. METHODS The algorithms autopopulated TSs using data from billing records and an institutional cancer registry. A nurse practitioner used the medical record to verify the accuracy of the information and made corrections electronically. Inaccurate and missing data were considered errors. We described and investigated reasons for errors in the automatically generated TSs. RESULTS We enrolled a heterogeneous population of 43 survivors of HNC. Using billing data, the information on primary site, lymph node status, radiation, and chemotherapy use was accurate in 93%, 95%, 93%, and 95% of patients, respectively. Billing data captured surgery accurately in 77% of patients; once an omitted billing code was identified, accuracy increased to 98%. Chemotherapies were captured in 90% of patients. Using the cancer registry, month and year of diagnosis were accurate in 91% of cases; stage was accurate in 28% of cases. Reprogramming the algorithm to ascertain clinical stage when pathologic stage was unavailable resulted in 100% accuracy. The algorithms inconsistently identified radiation receipt and treating physicians from billing data. CONCLUSION It is feasible to automatically and accurately generate most components of TSs for HNC using billing and cancer registry data, although clinical review is necessary in some cases.
Collapse
Affiliation(s)
- Shrujal S Baxi
- 1 Memorial Sloan-Kettering Cancer Center, New York, NY.,2 Weill Cornell Medical College, New York, NY
| | - Ranjit Sukhu
- 1 Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | - Andrew Salner
- 1 Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - Mary S McCabe
- 1 Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Talya Salz
- 1 Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
27
|
Salz T, Salner AL, Raghunathan NJ, McCabe MS, Dornelas E, Finitsis D, Corcoran S, Fortier E, Weber R, Tin A, Vickers AJ, Oeffinger KC, Baxi SS. Using patient-reported outcomes measures to tailor care for complex cancer survivors: A feasibility study of HN-STAR. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e22210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Talya Salz
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | | | | | | | - Ryan Weber
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Amy Tin
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | |
Collapse
|
28
|
Corcoran S, Thom B, Decker K. Electronic patient-reported outcomes (ePRO) in survivorship practice. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.7_suppl.79] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
79 Background: Use of patient-reported outcomes (PRO) is a well-recognized method of assessing long-term and late effects in cancer survivors. Our institution incorporated PRO in survivorship clinics in 2007, but to improve care delivery and practice efficiency, paper PRO were adapted to an electronic platform (ePRO) in 2017. This presentation describes our transition to ePRO in the survivorship setting: patient, provider, and administrator experiences are highlighted, and evaluation metrics are presented. Methods: Steps to convert PRO from paper to electronic format included collaborating with informatics staff to construct the ePRO; including institution-wide standardized language for demographic questions and symptom assessment (Common Terminology Criteria for Adverse Events); and customizing the ePRO, with input from oncologists and survivorship nurse practitioners. Patients with an institutional portal account receive a notification with the ePRO link 1 week prior to their visit, and patients without an account complete the survey on their appointment day in the waiting room on a tablet. Patients unable or unwilling to complete the ePRO do so on paper. To evaluate the transition to ePRO, we gathered usage data and administered a satisfaction survey to patients and providers. Results: Since ePRO initiation, 295 patients have completed the PRO: 71% on tablet, 19% on paper, and 11% via patient portal (only 34% of patients had portal accounts). Initial survey results suggest both patients and providers are satisfied using ePRO: complete survey data, along with qualitative descriptions of experiences, will be presented. Conclusions: Clinicians reported a positive experience reviewing post-treatment sequelae electronically in advance of the visit, allowing them to better prepare for the encounter. Based on clinician feedback, report modifications are underway, and next steps include adding symptom trends to the report and working with informatics to increase portal enrollment among survivors. We anticipate that as ePRO use becomes more widespread across the institution, greater assessment capability and improved monitoring and management of late-effects will occur, positively impacting outcomes for cancer survivors.
Collapse
Affiliation(s)
| | | | - Katie Decker
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
29
|
Winters ZE, Afzal M, Rutherford C, Holzner B, Rumpold G, da Costa Vieira RA, Hartup S, Flitcroft K, Bjelic-Radisic V, Oberguggenberger A, Panouilleres M, Mani M, Catanuto G, Douek M, Kokan J, Sinai P, King MT, Spillane A, Snook K, Boyle F, French J, Elder E, Chalmers B, Kabir M, Campbell I, Wong A, Flay H, Scarlet J, Weis J, Giesler J, Bliem B, Nagele E, del Angelo N, Andrade V, Assump¸ão Garcia D, Bonnetain F, Kjelsberg M, William-Jones S, Fleet A, Hathaway S, Elliott J, Galea M, Dodge J, Chaudhy A, Williams R, Cook L, Sethi S, Turton P, Henson A, Gibb J, Bonomi R, Funnell S, Noren C, Ooi J, Cocks S, Dawson L, Patel H, Bailey L, Chatterjee S, Goulden K, Kirk S, Osborne W, Harter L, Sharif MA, Corcoran S, Smith J, Prasad R, Doran A, Power A, Devereux L, Cannon J, Latham S, Arora P, Ridgway S, Coulding M, Roberts R, Absar M, Hodgkiss T, Connolly K, Johnson J, Doyle K, Lunt N, Cooper M, Fuchs I, Peall L, Taylor L, Nicholson A. International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction. Br J Surg 2017; 105:209-222. [PMID: 29116657 DOI: 10.1002/bjs.10656] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Revised: 03/02/2017] [Accepted: 06/23/2017] [Indexed: 11/12/2022]
Abstract
Abstract
Background
The aim was to carry out phase 4 international field-testing of the European Organisation for Research and Treatment of Cancer (EORTC) breast reconstruction (BRECON) module. The primary objective was finalization of its scale structure. Secondary objectives were evaluation of its reliability, validity, responsiveness, acceptability and interpretability in patients with breast cancer undergoing mastectomy and reconstruction.
Methods
The EORTC module development guidelines were followed. Patients were recruited from 28 centres in seven countries. A prospective cohort completed the QLQ-BRECON15 before mastectomy and the QLQ-BRECON24 at 4–8 months after reconstruction. The cross-sectional cohort completed the QLQ-BRECON24 at 1–5 years after reconstruction, and repeated this 2–8 weeks later (test–retest reliability). All participants completed debriefing questionnaires.
Results
A total of 438 patients were recruited, 234 in the prospective cohort and 204 in the cross-sectional cohort. A total of 414 reconstructions were immediate, with a comparable number of implants (176) and donor-site flaps (166). Control groups comprised patients who underwent two-stage implant procedures (72, 75 per cent) or delayed reconstruction (24, 25 per cent). Psychometric scale validity was supported by moderate to high item-own scale and item-total correlations (over 0·5). Questionnaire validity was confirmed by good scale-to-sample targeting, and computable scale scores exceeding 50 per cent, except nipple cosmesis (over 40 per cent). In known-group comparisons, QLQ-BRECON24 scales and items differentiated between patient groups defined by clinical criteria, such as type and timing of reconstruction, postmastectomy radiotherapy and surgical complications, with moderate effect sizes. Prospectively, sexuality and surgical side-effects scales showed significant responsiveness over time (P < 0·001). Scale reliability was supported by high Cronbach's α coefficients (over 0·7) and test–retest (intraclass correlation more than 0·8). One item (finding a well fitting bra) was excluded based on high floor/ceiling effects, poor test–retest and weak correlations in factor analysis (below 0·3), thus generating the QLQ-BRECON23 questionnaire.
Conclusion
The QLQ-BRECON23 is an internationally validated tool to be used alongside the EORTC QLQ-C30 (cancer) and QLQ-BR23 (breast cancer) questionnaires for evaluating quality of life and satisfaction after breast reconstruction.
Collapse
Affiliation(s)
- Z E Winters
- Breast Cancer Surgery Patient-Reported and Clinical Outcomes Research Group, University of Bristol, School of Clinical Sciences, Southmead Hospital, Bristol, UK
- Surgical and Interventional Trials Unit, Division of Surgical Sciences, University College London, London, UK
- Quality of Life Office, School of Psychology, Faculty of Science, University of Sydney, New South Wales, Australia
| | - M Afzal
- Breast Cancer Surgery Patient-Reported and Clinical Outcomes Research Group, University of Bristol, School of Clinical Sciences, Southmead Hospital, Bristol, UK
| | - C Rutherford
- Quality of Life Office, School of Psychology, Faculty of Science, University of Sydney, New South Wales, Australia
| | - B Holzner
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria
| | - G Rumpold
- Department of Medical Psychology, Evaluation Software Development, Rum, Austria
| | | | - S Hartup
- St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - K Flitcroft
- Breast and Surgical Oncology, Poche Centre, University of Sydney, New South Wales, Australia
| | - V Bjelic-Radisic
- Department of Breast Surgery and Gynaecology, Medical University Graz, Graz, Austria
| | - A Oberguggenberger
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria
| | - M Panouilleres
- Department of Plastic Surgery, Besançon University Hospital, Besançon, France
| | - M Mani
- Department of Surgical Sciences, Plastic and Reconstructive Surgery, Uppsala University, Uppsala, Sweden
| | - G Catanuto
- Multidisciplinary Breast Care, Cannizzaro Hospital, Catania, Italy
| | - M Douek
- Department of Surgical Oncology, Guy's Hospital, London, London, UK
| | - J Kokan
- Cancer Resource Centre, Macclesfield Hospital, Macclesfield, UK
| | - P Sinai
- Breast Cancer Surgery Patient-Reported and Clinical Outcomes Research Group, University of Bristol, School of Clinical Sciences, Southmead Hospital, Bristol, UK
| | - M T King
- Quality of Life Office, School of Psychology, Faculty of Science, University of Sydney, New South Wales, Australia
- Sydney Medical School, Faculty of Medicine, University of Sydney, New South Wales, Australia
| | - A Spillane
- Poche Centre, Sydney, New South Wales, Australia
| | - K Snook
- Poche Centre, Sydney, New South Wales, Australia
| | - F Boyle
- Poche Centre, Sydney, New South Wales, Australia
| | - J French
- The Crown Princess Mary Westmead Breast Cancer Centre and Specialist Services, Sydney, New South Wales, Australia
| | - E Elder
- The Crown Princess Mary Westmead Breast Cancer Centre and Specialist Services, Sydney, New South Wales, Australia
| | - B Chalmers
- The Crown Princess Mary Westmead Breast Cancer Centre and Specialist Services, Sydney, New South Wales, Australia
| | - M Kabir
- The Crown Princess Mary Westmead Breast Cancer Centre and Specialist Services, Sydney, New South Wales, Australia
| | | | - A Wong
- Waikato Hospital, Hamilton, New Zealand
| | - H Flay
- Waikato Hospital, Hamilton, New Zealand
| | - J Scarlet
- Waikato Hospital, Hamilton, New Zealand
| | - J Weis
- University of Freiburg, Freiberg, Germany
| | - J Giesler
- University of Freiburg, Freiberg, Germany
| | - B Bliem
- Medical University Graz, Graz, Austria
| | - E Nagele
- Medical University Graz, Graz, Austria
| | | | - V Andrade
- Barretos Cancer Hospital, Sao Paolo, Brazil
| | | | - F Bonnetain
- Besançon University Hospital, Besançon, France
| | | | - S William-Jones
- Clinical Research Network, West Midlands, Queen-s Hospital, Burton upon Trent, UK
| | - A Fleet
- Clinical Research Network, West Midlands, Queen-s Hospital, Burton upon Trent, UK
| | - S Hathaway
- Clinical Research Network, West Midlands, Queen-s Hospital, Burton upon Trent, UK
| | - J Elliott
- Clinical Research Network, West Midlands, Queen-s Hospital, Burton upon Trent, UK
| | - M Galea
- Cancer Research Unit, Great Western Hospital, Swindon, UK
| | - J Dodge
- Cancer Research Unit, Great Western Hospital, Swindon, UK
| | - A Chaudhy
- Cancer Research Unit, Great Western Hospital, Swindon, UK
| | | | - L Cook
- Guy's Hospital, London, UK
| | | | - P Turton
- Leeds Teaching Hospital, Leeds, UK
| | - A Henson
- Leeds Teaching Hospital, Leeds, UK
| | - J Gibb
- Leeds Teaching Hospital, Leeds, UK
| | - R Bonomi
- Worthing Hospital, Western Sussex Hospitals, Worthing, UK
| | - S Funnell
- Worthing Hospital, Western Sussex Hospitals, Worthing, UK
| | - C Noren
- Worthing Hospital, Western Sussex Hospitals, Worthing, UK
| | - J Ooi
- Royal Bolton Hospital, Bolton, UK
| | - S Cocks
- Royal Bolton Hospital, Bolton, UK
| | - L Dawson
- Royal Bolton Hospital, Bolton, UK
| | - H Patel
- Royal Bolton Hospital, Bolton, UK
| | - L Bailey
- Royal Bolton Hospital, Bolton, UK
| | | | | | - S Kirk
- Salford Royal Hospital, UK
| | | | | | | | | | - J Smith
- Stepping Hill Hospital, Stockport, UK
| | - R Prasad
- Royal AlbertEdward Infirmary, Wigan, UK
| | - A Doran
- Royal AlbertEdward Infirmary, Wigan, UK
| | - A Power
- Royal AlbertEdward Infirmary, Wigan, UK
| | | | - J Cannon
- Royal AlbertEdward Infirmary, Wigan, UK
| | - S Latham
- Royal AlbertEdward Infirmary, Wigan, UK
| | - P Arora
- Tameside General Hospital, Ashton-under-Lyne, UK
| | - S Ridgway
- Tameside General Hospital, Ashton-under-Lyne, UK
| | - M Coulding
- Tameside General Hospital, Ashton-under-Lyne, UK
| | - R Roberts
- Tameside General Hospital, Ashton-under-Lyne, UK
| | - M Absar
- North ManchesterGeneral Hospital, Manchester, UK
| | - T Hodgkiss
- North ManchesterGeneral Hospital, Manchester, UK
| | - K Connolly
- North ManchesterGeneral Hospital, Manchester, UK
| | - J Johnson
- North ManchesterGeneral Hospital, Manchester, UK
| | - K Doyle
- North ManchesterGeneral Hospital, Manchester, UK
| | - N Lunt
- Cancer Resource Centre, Macclesfield Hospital, Macclesfield, UK
| | - M Cooper
- Bristol Breast Care Centre, Southmead Hospital, Bristol, UK
| | - I Fuchs
- Bristol Breast Care Centre, Southmead Hospital, Bristol, UK
| | - L Peall
- Bristol Breast Care Centre, Southmead Hospital, Bristol, UK
| | - L Taylor
- Bristol Breast Care Centre, Southmead Hospital, Bristol, UK
| | - A Nicholson
- Bristol Breast Care Centre, Southmead Hospital, Bristol, UK
| |
Collapse
|
30
|
Salz T, McCabe MS, Oeffinger KC, Schnall RB, Corcoran S, Vickers AJ, Salner AL, Dornelas EA, Raghunathan NJ, Fortier E, Finitsis D, Baxi SS. Survivor feedback on a late effects-oriented survivorship care plan for head and neck cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e21596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21596 Background: Survivorship care plans (SCPs) typically include generic advice for the management of late effects (LEs) that can occur, rather than addressing LEs that the survivor actually has. We developed a platform called HN-STAR that uses electronic patient-reported outcomes (ePROs) and evidence-based LE management to generate a personalized SCP for survivors of head and neck cancer (HNC), a population vulnerable to various LEs. We assessed HNC survivors’ experiences with HN-STAR to ensure its acceptability and usefulness. Methods: Disease-free HNC survivors at two cancer hospitals used HN-STAR in conjunction with a routine survivorship visit. Prior to the visit, survivors used a validated ePRO measure (PRO-CTCAE) to report up to 22 physical LEs. Based on clinic visit discussions, HN-STAR generated an SCP that included a treatment summary and LE management plans. Survivors indicated their level of agreement to statements regarding the ease of use of the ePROs, content of the SCP, and intentions to adhere to LE management recommendations. Results: 47 survivors completed surveys (mean 5.4 years from treatment completion). Most were white (89%), male (85%), had an oropharynx tumor (58%), and received multimodality therapy (81%). More than half (51%) experienced at least 9 of the 22 LEs in the last 30 days (mean 8.2 per person). Most survivors reported that completing ePROs improved the discussions with their provider (98%), the quality of their care (96%), and their communication with their provider (98%). 91% agreed the SCP was the right length, and 98% agreed it was easy to follow. 98% intended to follow at least some of the recommendations for LEs management, and 98% reported feeling confident that they could follow the recommendations. The majority agreed that the SCP accurately summarized the clinic visit (98%), they would refer back to the SCP (98%), they trust the SCP (100%), and they plan to share the SCP with a primary care provider (87%). Conclusions: Among HNC survivors, an automatically generated SCP that was tailored to their LEs was acceptable, was trusted, and provided recommendations they intended to follow. Patient-centered SCPs that focus on existing LEs hold promise as a means to help survivors manage LEs.
Collapse
Affiliation(s)
- Talya Salz
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, Goodman KA, Margolies A, Matasar MJ, Noy A, Goldfarb SB. Cancer and Fertility Program Improves Patient Satisfaction With Information Received. J Clin Oncol 2016; 34:1780-6. [PMID: 27044937 DOI: 10.1200/jco.2015.64.5168] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
PURPOSE A cancer and fertility program was established at a large cancer center to support clinicians in discussing treatment-related fertility risks and fertility preservation (FP) options with patients and in referring patients to reproductive specialists. The program provides resources, clinician education, and fertility clinical nurse specialist consultation. This study evaluated the program's impact on patient satisfaction with information received. PATIENTS AND METHODS Retrospective cross-sectional surveys assessed satisfaction before (cohort 1 [C1]) and after (cohort 2 [C2]) program initiation. Questionnaires were investigator-designed, gender-specific, and anonymous. RESULTS Most C1 (150 males, 271 females) and C2 (120 males, 320 females) respondents were 2 years postdiagnosis; the most frequently reported cancers were testicular, breast, and lymphoma. A significant difference in satisfaction with the amount of information received was seen between C1 and C2. For males, satisfaction with information on fertility risks was high in both cohorts but significantly greater in C2 for information on sperm banking (χ(2) = 9.3, P = .01) and finding a sperm bank (χ(2) = 13.3, P = .001). For females, satisfaction with information was significantly greater in C2 for information on fertility risks (χ(2) = 62.1, P < .001), FP options (χ(2) = 71.9, P < .001), help with decision making (χ(2) = 80.2, P < .001), and finding a reproductive endocrinologist (χ(2) = 60.5, P < .001). Among patients who received and read information materials, 96% of males and 99% of females found them helpful. Among C2 females, fertility clinical nurse specialist consultation was associated with significantly greater satisfaction with information on FP options (χ(2) = 11.2, P = .004), help with decision making (χ(2) = 10.4, P = .006), and finding a reproductive endocrinologist (χ(2) = 22.6, P < .001), with 10% reporting lack of knowledge as a reason for not pursuing FP. CONCLUSION Improvements in patient satisfaction with information received demonstrate the potential for fertility programs in cancer care settings to improve the quality of clinician-patient discussions about fertility.
Collapse
Affiliation(s)
- Joanne F Kelvin
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Bridgette Thom
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Catherine Benedict
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Jeanne Carter
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Stacie Corcoran
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Maura N Dickler
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Karyn A Goodman
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Allison Margolies
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Matthew J Matasar
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Ariela Noy
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| | - Shari B Goldfarb
- Joanne F. Kelvin, Bridgette Thom, Jeanne Carter, Stacie Corcoran, Maura N. Dickler, Matthew J. Matasar, Ariela Noy, and Shari B. Goldfarb, Memorial Sloan Kettering Cancer Center, New York; Catherine Benedict, Hofstra Northwell School of Medicine, Manhasset, NY; Karyn A. Goodman, University of Colorado School of Medicine, Aurora, CO; and Allison Margolies, Newton-Wellesley Hospital, Newton, MA
| |
Collapse
|
33
|
Economou D, Corcoran S. Incorporating a Survivorship Clinic Into Practice. J Adv Pract Oncol 2016; 7:343-346. [PMID: 29152404 PMCID: PMC5679056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Portlock CS, Hamlin PA, Gerecitano JF, Noy A, Palomba ML, Walkley J, Corcoran S, Migliacci J, Schoder H, Papanicolaou G, Markowitz AJ. A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma. Tumor Microenviron Ther 2016; 2:14-18. [PMID: 26798624 DOI: 10.1515/tumor-2015-0001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND We have prospectively studied a three month course of clarithromycin (substituted by Prevpac®, lansoprazole/ amoxicillin/ clarithromycin, in the first two wks when stool H pylori+) for non-bulky, advanced stage indolent lymphoma. These patients are often candidates for expectant monitoring and it is during this period that a window of opportunity may exist to identify and treat associated infections. METHODS All previously untreated patients with a new diagnosis of indolent lymphoma (FL and non-FL) meeting GELF criteria were treated with 12 weeks of clarithromycin. There were 32 evaluable patients, 4 of whom had stool H pylori. RESULTS At one month post-antibiotic therapy, we have observed lymphoma responses in 7 of 32 patients (21.9%). Two additional patients had objective response during followup (28.1% overall response). The median treatment free survival for antibiotic responders is 69.9 months and for non-responders, 30.6 months (p = 0.019). CONCLUSION Three response patterns have been noted, perhaps suggestive of an immune-mediated response -- prompt PET negative; flair with delayed PET negative response; and gradual continuous improvement. This prospective study appears promising, may be a step toward developing a lymphoma prevention strategy by reducing "antigen drive," and deserves further clinical/biological study. http://clinicaltrials.gov/show/NCT00461084.
Collapse
Affiliation(s)
- Carol S Portlock
- Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Paul A Hamlin
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - John F Gerecitano
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - Ariela Noy
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - Maria Lia Palomba
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - Janelle Walkley
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - Stacie Corcoran
- Memorial Sloan Kettering Cancer Center, Office of Physician-in-Chief, 1275 York Avenue New York, NY, 10065 USA
| | - Jocelyn Migliacci
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - Heiko Schoder
- Memorial Sloan Kettering Cancer Center, Department of Radiology, 1275 York Avenue New York, NY, 10065 USA
| | - Genovefa Papanicolaou
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| | - Arnold J Markowitz
- Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA
| |
Collapse
|
35
|
|
36
|
Portlock CS, Hamlin PA, Gerecitano JF, Noy A, Palomba ML, Walkley J, Corcoran S, Papanicolaou GA, Markowitz A. Infectious disease associations in advanced stage, indolent lymphoma (follicular, FL, and nonfollicular, nFL): A prospective trial of antibiotic therapy. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.8571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8571 Background: The antigen-drive association of gastric MALT with H. pylori (HP) is well recognized. Successful antibiotic (Ab) can result in lymphoma remission. We have studied a 3 mo course of clarithromycin (substituting lansoprazole/amoxicillin/clarithromycin, Prevpak, in the first 2 wks if HP +) in non-bulky, advanced stage indolent lymphoma as the first step to such a lymphoma treatment/prevention strategy. Methods: Patients with new diagnosis indolent lymphoma (FL and nFL), stages II (abdominal), III and IV fulfilling GELF criteria for observation were eligible. Stool HP done in all patients. Hepatitis B and C positive excluded. All patients had CT and PET prior to and 1 mo post Ab. Results: 32 evaluable patients were enrolled: 14 females, 18 males; median age, 53.5 years (36- 81); 22 FL, 10 nFL; stage II (2), III (16), and IV (14). HP + patients: 4 (3 FL, 1 nFL). We have observed lymphoma responses 1 mo post Ab in 7 of 32 (Table). With continued followup post Ab, best response to date in 9 of 32: PET CR ( 2 FL; 2 nFL); CT CR/PR ( 1/3 FL, 1/0 nFL). Median followup for all patients, 23.7 mos; and for those not needing lymphoma treatment, 54.9 mos. To date, no patient with PET CR has required lymphoma treatment (22.5+ to 62.8+ mos). Among 22 with FL, 8 have progressed, 3 had histologic transformation, possibly suggesting a different biology. Conclusions: H pylori eradication/3 mos clarithromycin has achieved lymphoma responses in advanced stage indolent lymphoma. PET negative CRs have been durable for 22.5 – 62.8 + mos following Ab alone. This prospective study may be a first step toward developing a lymphoma prevention strategy and deserves further clinical/biological study. Clinical trial information: NCT00461084. [Table: see text]
Collapse
Affiliation(s)
- Carol S. Portlock
- Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | - Ariela Noy
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Maria Lia Palomba
- Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | |
Collapse
|
37
|
Ogata CM, Sanishvili R, Hilgart M, Stepanov S, Becker M, Nagarajan V, Xu S, Makarov O, Pothineni S, Yoder D, Corcoran S, Smith JL, Fischetti RF. Automation and remote control at GM/CA CAT at the APS. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311093019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
38
|
Goldfarb SB, Kelvin JF, Thom B, Kaplan J, Margolies A, Corcoran S, McCabe MS, Hudis C, Basch EM, Dickler MN. Fertility preservation: Are we telling patients what they want to know? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Aung A, Corcoran S, Nagalingam V, Paul E, Newnham H. Prevalence, Associations and Risk Factors for Orthostatic Hypotension in Medical, Surgical and Trauma Inpatients: An Observational Cohort Study. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Delany C, McDonnell R, Robson M, Corcoran S, Fitzpatrick C, De La Harpe D. Folic acid supplement use in the prevention of neural tube defects. Ir Med J 2011; 104:12-15. [PMID: 21387878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In 2008, planned folic acid fortification for the prevention of Neural Tube Defects (NTD) was postponed. Concurrently, the economic recession may have affected dietary folic acid intake, placing increased emphasis on supplement use. This study examined folic acid supplement use in 2009. A cross-sectional survey of 300 ante-natal women was undertaken to assess folic acid knowledge and use. Associations between demographic, obstetric variables and folic acid knowledge and use were examined. A majority, 284/297 (96%), had heard of folic acid, and 178/297 (60%) knew that it could prevent NTD. Most, 270/297 (91%) had taken it during their pregnancy, but only 107/297 (36%) had used it periconceptionally. Being older, married, planned pregnancy and better socioeconomic status were associated with periconceptional use. Periconceptional folic acid use in 2009 was very low, little changed from economic status were associated with periconceptional use. Periconceptional folic acid use in 2009 was very low, little changed from earlier years. Continuous promotion efforts are necessary. Close monitoring of folic acid intake and NTD rates is essential, particularly in the absence of fortification.
Collapse
Affiliation(s)
- C Delany
- RCSI, 123 St Stephen's Green, Dublin 2
| | | | | | | | | | | |
Collapse
|
41
|
Goldfarb SB, Kelvin JF, Thom B, Kaplan J, Corcoran S, Margolies A, McCabe MS, Norton L, Hudis C, Basch E, Dickler MN. Abstract P2-14-08: Patient Perspectives on Information Communicated Regarding Effects of Treatment on Fertility. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many breast cancer survivors diagnosed during their reproductive years desire to have children after treatment and are distressed about the possibility of treatment-induced infertility. Informing patients about fertility preservation options before therapy may optimize quality of life after treatment. This study was undertaken to evaluate the information patients received about effects of therapy on fertility, early menopause, and fertility preservation options. Methods:
An IRB approved cross-sectional study was performed to evaluate patient perceptions of the impact of treatment on fertility and early menopause. The survey was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) for patients ages 18-45, with items derived from existing surveys in the literature and input from a multidisciplinary committee. We evaluated two groups of patients, one who had completed treatment and the other who was currently undergoing therapy. Surveys were mailed to 395 women who began treatment (all modalities) for breast cancer at MSKCC between 7/1/07 and 6/30/08. A second cohort of patients (n=35) completed surveys during patient visits to breast cancer medicine ambulatory clinics
between 3/22/2010 and 4/8/2010.
Results:
The survey was completed by 159 pts. (129/395 and 30/35). At the time of diagnosis, 69% (110/159) had children and 45% (70/156) were interested in having children. 79% (123/155) reported that the impact of treatment on fertility was discussed with them before initiating therapy. A healthcare provider initiated the discussion 54% (83/155) of the time. However, only 35% (54/152) and 47% (71/150) of women felt they received an adequate amount of information about the effect of cancer treatment on fertility and menopause, respectively. Based on their ranking, patients preferred to receive fertility information in person either from their physician or a fertility specialist, or through written material. After treatment, 5 patients attempted pregnancy (7 naturally, 1 with assisted technology), yielding 8 live births. Conclusions:
Many breast cancer survivors wish to have children after treatment. To optimize success, patients should be adequately informed about the effects of therapy on fertility, early menopause, and options for fertility preservation. These findings are informing an institution-wide fertility program.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-14-08.
Collapse
Affiliation(s)
- SB Goldfarb
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - JF Kelvin
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B Thom
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J Kaplan
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S Corcoran
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A Margolies
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - MS McCabe
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L Norton
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - E Basch
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - MN. Dickler
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
42
|
Sanishvili R, Xu S, Nagarajan V, Yoder D, Becker M, Stepanov S, Pothineni S, Hilgart M, Makarov O, Corcoran S, Akey D, Smith J, Fischetti R. Small beams can play big roles in macromolecular crystallography. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308098887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
Fischetti R, Sanishvili R, Yoder D, Vogt S, Rosenbaum G, Benn R, Corcoran S, Makarov O, Xu S, Nagarajan V, Becker M, Pothineni S, Smith J. Probing radiation damage with a 1-micron beam. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Portlock CS, Hamlin P, Noy A, Chey W, Gaydos CA, Palomba L, Schwartz I, Corcoran S, Rosenzweig L, Walker D, Papanicolaou G, Markowitz A. Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. Ann Oncol 2007; 19:254-8. [PMID: 17965114 DOI: 10.1093/annonc/mdm484] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tumor can result in lymphoma remission. We prospectively identified/treated infections in nonbulky, advanced stage indolent lymphoma (follicular; nonfollicular lymphoma) eligible for observation. MATERIALS AND METHODS Stool H. pylori, hepatitis C and Borrelia serologies, Borrelia and Chlamydia fixed tissue PCR, Chlamydia peripheral blood mononuclear cell PCR and hydrogen breath test for small bowel bacterial overgrowth (SBBO) were obtained. RESULTS Fifty-six patients were enrolled. Positive infections: H. pylori (13); hepatitis C (3); SBBO (11). Negative: Borrelia (13); Chlamydophila psittaci (12, except one PCR). Lymphoma responses to antimicrobial therapy: H. pylori [one complete response (CR), 24+ months; one transient near CR]; hepatitis C [two CRs, 18+ and 30+ months; one partial response (PR) but hepatitis C virus persistent]; SBBO (one PR, 30+ months). Patients with associated infections, but without lymphoma CR, have required lymphoma treatment sooner than those without initial infections (treatment-free survival at 23.4 months median follow-up, 40.5% versus 74.7%, P = 0.01), indicating a different biology. CONCLUSION Infections are common in advanced stage indolent lymphoma (37.5% in our series). Anecdotal lymphoma responses have been seen and three have been durable CRs (18 to 30+ months) with infection eradication alone. The identification and treatment of associated infections may be a first step towards developing a lymphoma prevention strategy.
Collapse
Affiliation(s)
- C S Portlock
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Jarvie EM, North Laidler VJ, Corcoran S, Bassil A, Sanger GJ. Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br J Pharmacol 2007; 150:455-62. [PMID: 17211452 PMCID: PMC2189716 DOI: 10.1038/sj.bjp.0707118] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND AND PURPOSE Motilin or 5-HT4 receptor agonists stimulate gastrointestinal motility. Differences in activity are suggested but direct comparisons are few. A method was devised to directly compare the gastric prokinetic activities of motilin, the motilin receptor agonist, erythromycin, and the 5-HT4 receptor agonist, tegaserod. EXPERIMENTAL APPROACH Gastric prokinetic-like activity was assessed by measuring the ability to facilitate cholinergically-mediated contractions evoked by electrical field stimulation (EFS) in rabbit isolated stomach. Comparisons were made between potency, maximal activity and duration of responses. KEY RESULTS Rabbit motilin (r.motilin) 0.003-0.3 microM, [Nle13]motilin 0.003-0.3 microM, erythromycin 0.3-10 microM and tegaserod 0.1-10 microM caused concentration - dependent potentiation of EFS-evoked contractions. The potency ranking was r.motilin = [Nle13]motilin > tegaserod > erythromycin. The Emax ranking was r.motilin = [Nle13]motilin = erythromycin > tegaserod. Responses to r.motilin and [Nle13]motilin faded rapidly (t1/2 9 and 11 min, respectively) whereas those to erythromycin and tegaserod were maintained longer (t1/2 24 and 28 min). The difference did not appear to be due to peptide degradation. A second application of [Nle13]motilin was excitatory after 60 min contact and fade of the initial response (responses to 0.03 and 0.1 microM [Nle13]motilin were not different from those caused by the first application). CONCLUSIONS AND IMPLICATIONS Prokinetic-like activities of the 5-HT4 agonist tegaserod and the motilin receptor agonists were compared by measuring changes in cholinergically-mediated contractions. This novel approach highlighted important differences between classes (greater Emax of motilin, compared with tegaserod) and for the first time, within each class (short t1/2 for motilin, compared with erythromycin).
Collapse
Affiliation(s)
- E M Jarvie
- Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited New Frontiers Science Park, Harlow, Essex UK
| | - V J North Laidler
- Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited New Frontiers Science Park, Harlow, Essex UK
| | - S Corcoran
- Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited New Frontiers Science Park, Harlow, Essex UK
| | - A Bassil
- Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited New Frontiers Science Park, Harlow, Essex UK
| | - G J Sanger
- Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited New Frontiers Science Park, Harlow, Essex UK
- Author for correspondence:
| |
Collapse
|
46
|
Abstract
BACKGROUND Streptococcal throat infections and HLA Cw6 (Cw*06) have been implicated in the pathogenesis of psoriasis, particularly in the guttate form. OBJECTIVES To study 105 Irish patients with psoriasis to investigate the relationship between streptococcal infections and Cw*06. METHODS The patients were divided into two groups: those with guttate psoriasis or guttate flare (guttate group, GG, n=64) and those with chronic plaque psoriasis (chronic plaque group, CPG, n=41). RESULTS The incidence of Cw*06 was 86% in the GG and 73% in the CPG, which was not significantly different (P=0.1725) but the incidence in both groups was significantly higher than in an Irish control group (18%) (P<0.0001 vs. GG and P<0.0001 vs. CPG). Evidence for streptococcal infection was higher in the GG (56%) than in the CPG (32%) (P=0.0231). Of those patients with evidence of streptococcal infection, 30 of 36 GG (83%) and nine of 13 CPG (69%) patients possessed the Cw*06 genotype. CONCLUSIONS Thus, not all patients with streptococcal-related psoriasis carry Cw*06. The role of Cw*06 in psoriasis, if any, has yet to be determined.
Collapse
Affiliation(s)
- L Fry
- Faculty of Medicine, Imperial College, London, UK, and The Skin Hospital, Dublin 2, Ireland
| | | | | | | | | | | |
Collapse
|
47
|
Fischetti RF, Stepanov S, Xu S, Makarov O, Urakhchin A, Sanishvili R, Smith WW, Yoder D, Benn R, Corcoran S, Devarapalli S, Diete W, Schwoerer-Boehing M, Signorato R, Berman LE, Smith JL. GM/CA canted undulator beamlines for protein crystallography. Acta Crystallogr A 2005. [DOI: 10.1107/s0108767305094110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Portlock CS, Noy A, Hamlin P, Qin J, Rosenzweig L, Corcoran S, Chey W, Papanicolaou G, Markowitz A. Infectious disease associations in indolent lymphoma (follicular, FL and non-follicular, nFL): Developing a lymphoma prevention strategy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. S. Portlock
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - A. Noy
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - P. Hamlin
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - J. Qin
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - L. Rosenzweig
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - S. Corcoran
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - W. Chey
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - G. Papanicolaou
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| | - A. Markowitz
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Michigan, Ann Arbor, MI
| |
Collapse
|
49
|
Dass NB, Munonyara M, Bassil AK, Hervieu GJ, Osbourne S, Corcoran S, Morgan M, Sanger GJ. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 2003; 120:443-53. [PMID: 12890514 DOI: 10.1016/s0306-4522(03)00327-0] [Citation(s) in RCA: 139] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The peptide hormone ghrelin is known to be present within stomach and, to a lesser extent, elsewhere in gut. Although reports suggest that gastric function may be modulated by ghrelin acting via the vagus nerve, the gastrointestinal distribution and functions of its receptor, the growth hormone secretagogue receptor (GHS-R), are not clear and may show signs of species-dependency. This study sought to determine the cellular localisation and distribution of GHS-R-immunoreactivity (-Ir) using immunofluorescent histochemistry and explore the function of ghrelin in both human and rat isolated gastric and/or colonic circular muscle preparations in which nerve-mediated responses were evoked by electrical field stimulation. The expression of GHS-R-Ir differed to a greater extent between species than between gut regions of the same species. Both the human and rat gastric and colonic preparations (n=3 each) expressed GHS-R-Ir within neuronal cell bodies and fibres, cells associated with gastric glands and putative entero-endocrine and/or mast cells. Smooth muscle cells and epithelia were devoid of GHS-R-Ir and only rat preparations expressed GHS-R-Ir on nerve fibres associated with the muscle layers. GHS-R-Ir was fully competed in all cases in pre-adsorption studies and antiserum specificity was confirmed using a cell line transiently expressing the rat GHS-R. In rat isolated forestomach circular muscle, ghrelin 0.1-10 microM had no effect on smooth muscle tension but concentration-dependently facilitated the amplitude of contractions evoked by excitatory nerve stimulation (n=4-7; P<0.05 for each concentration versus vehicle; n=18). When examined under similar conditions, in both rat distal colon (n=4-6, P>0.05 each) and human ascending (n=3) and sigmoid (n=1) colon, these concentrations of ghrelin were without effect (P>0.05 each). The data suggest that ghrelin has the potential to profoundly affect gastrointestinal functions in both species and at least one of these functions is to exert a gastric prokinetic activity. Moreover, we suggest that this activity of ghrelin is mediated via the enteric nervous system, in addition to known vagus nerve-dependent mechanisms.
Collapse
Affiliation(s)
- N B Dass
- Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, UK
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003; 148:670-9. [PMID: 12752123 DOI: 10.1046/j.1365-2133.2003.05287.x] [Citation(s) in RCA: 222] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Toll-like receptors (TLRs) are part of the innate immune system involved in the response to microbial pathogens. TLR2 recognizes various ligands expressed by Gram-positive bacteria, while TLR3, TLR4 and TLR5 are specific for double-stranded RNA, Gram-negative lipopolysaccharides and bacterial flagellin, respectively. OBJECTIVES To determine, firstly, whether epidermal keratinocytes of normal skin express TLRs and, secondly, whether modulation of TLR expression occurs in psoriasis, an inflammatory skin disease associated with certain microorganisms such as streptococci, staphylococci and yeasts. METHODS Eight samples of normal, and 15 samples of lesional and nonlesional psoriatic skin were stained with polyclonal antibodies specific for TLR1-5 using an avidin-biotin-peroxidase technique. RESULTS Epidermal keratinocytes in normal skin constitutively expressed TLR1, TLR2 and TLR5, while TLR3 and TLR4 were, in most cases, barely detectable. Cytoplasmic TLR1 and TLR2 were expressed throughout the epidermis, with higher staining of the latter on basal keratinocytes, while TLR5 expression was concentrated in the basal layer. In contrast, in lesional epidermis from patients with psoriasis, TLR2 was more highly expressed on the keratinocytes of the upper epidermis than on the basal layer, while TLR5 was downregulated in basal keratinocytes compared with corresponding nonlesional psoriatic epidermis. In addition, nuclear TLR1 staining was observed in the upper layers of both nonlesional and lesional psoriatic epidermis, but not in that of normal skin. CONCLUSIONS These findings suggest that TLRs expressed by epidermal keratinocytes constitute part of the innate immune system of the skin. The relevance of altered keratinocyte TLR expression in psoriasis remains to be determined.
Collapse
Affiliation(s)
- B S Baker
- Department of Dermatology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, St Mary's Campus, Norfolk Place, Paddington, London W2 1PG, UK.
| | | | | | | | | |
Collapse
|